摘要
目的 探讨甲巯咪唑联合普萘洛尔在甲状腺功能亢进症(甲亢)治疗中的应用效果及不良反应。方法 88例甲亢患者,采用随机数字表法分为对照组和观察组,每组44例。对照组患者应用甲巯咪唑治疗,观察组患者应用甲巯咪唑联合普萘洛尔治疗。比较两组患者的治疗效果、不良反应发生率及治疗前后甲状腺激素[血清游离甲状腺素(FT_(4))、游离三碘甲状腺原氨酸(FT_(3))、促甲状腺激素(TSH)]水平。结果 观察组患者治疗总有效率为93.18%,高于对照组的77.27%,差异具有统计学意义(P<0.05)。治疗后,观察组患者FT_(4)(20.45±0.32)pmol/L、FT_(3)(6.54±0.10)pmol/L低于对照组的(25.10±0.73)、(9.50±0.12)pmol/L,TSH(0.34±0.15)μIU/ml高于对照组的(0.23±0.10)μIU/ml,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为6.82%,与对照组的11.36%比较,差异无统计学意义(P>0.05)。结论 甲巯咪唑联合普萘洛尔在甲亢治疗中应用效果显著,能够有效改善甲状腺激素水平,且不良反应发生率低,值得临床推广应用。
Objective To discuss the application effect and adverse reactions of adverse reactions of methimazole combined with propranolol in the treatment of hyperthyroidism.Methods A total of 88 hyperthyroidism patients were randomly divided into control group and observation group,with 44 cases in each group.The control group was treated with methimazole,and the observation group was treated with methimazole and propranolol.Both groups were compared in terms of therapeutic effect,incidence of adverse reactions and thyroid hormone[serum free thyroxine(FT_(4)),free triiodothyronine(FT_(3)),thyroid stimulating hormone(TSH)]levels before and after treatment.Results The total effective rate of the observation group was 93.18%,which was higher than that of 77.27%of the control group,and the difference was statistically significant(P<0.05).After treatment,FT_(4) of(20.45±0.32)pmol/L and FT3 of(6.54±0.10)pmol/L in the observation group were lower than those of(25.10±0.73)and(9.50±0.12)pmol/L in the control group;TSH of(0.34±0.15)μIU/ml in the observation group was higher than that of(0.23±0.10)μIU/ml in the control group;the differences were statistically significant(P<0.05).The incidence of adverse reactions was 6.82%in the observation group and 11.36%in the control group,and the difference was not statistically significant between the two groups(P>0.05).Conclusion Methimazole combined with propranolol has significant effect in the treatment of hyperthyroidism,which can effectively improve thyroid hormone levels,and the incidence of adverse reactions is low,which is worthy of clinical promotion and application.
作者
戴一姝
DAI Yi-shu(Kuandian Manchu Autonomous County Central Hospital,Dandong 118000,China)
出处
《中国现代药物应用》
2023年第10期121-123,共3页
Chinese Journal of Modern Drug Application
